Marijuana Sector News

4 9679

By Jason Spatafora @WolfofWeedSt

“I fear the Greeks, even those bearing gifts.”- Virgil

The DEA’s recent cannabis research expansion is a Harry Houdini inspired smoke show of misdirection all to set up the next trick; there I said it. While some view it as a positive first step, I tend to think it served a very deliberate function. Optically it played directly into expected vitriolic fallout from advocates, activists and media touts, all of which lined up to ignite their “DEA should reschedule cannabis” torches. In a “perfect world” scenario these people aren’t wrong, cannabis isn’t Heroin’s equal & 1+1=2, but just as fire cannot exist in a vacuum, neither can a rational cannabis debate. And while everyone on the side of reason is shouting in unison about rescheduling they failed to see that they might have just had their pockets picked. DEA’s policy statement that everyone seemed to ignore there are 33 words that have the potential to create the legal framework for the monopolization of Cannabis by means of an exclusionary application process.

Prologue – August 10th, 2016

Russ Baer, a staff coordinator for the Drug Enforcement Administration (DEA) media affairs wing gave a response to Steven Nelson of USNEWS.com via email. Nelson later shared a screen grab of the email via tweet. The statement made to him from this Drug Enforcement Administration staff coordinator read:

“Tomorrow morning (August 11th, 2016) the Drug Enforcement Administration will be making some important announcement regarding Marijuana related topics that will be published in the Federal Register. Because of your interest and/or prior engagement with the DEA on this subject, the DEA office of National Media Affairs is reaching out to you regarding these anticipated announcements.”

Over the next 24 hours social media was a blaze, with many people within the industry uncovering the fact that Rescheduling wouldn’t happen and that the DEA response would have to do with research. As expected, the incendiary scheduling of cannabis debate raged on into the following day.

August 11th, 2016

As expected, the Drug Enforcement Administration disappointed the advocates and activists of medical marijuana by not removing or rescheduling marijuana from its class 1 controlled substance status. Yet the DEA, in all of its benevolence, offered a consolation prize of sorts, by “deciding” to expand the study of Medical Marijuana for researchers, Universities & drug companies outside of the confines of a single federally legal facility. The facility, to refresh your memory is located at the University of Mississippi, (ranked 164th in Bio Sciences) and had up to this point been the sole research monopoly on legally grown marijuana, courtesy of the NIDA (National Institute on Drug Abuse).

DEA’s Misdirection Strategy

Over the next few days it seemed that every headline following the DEA’s deliberation was about the archaic rescheduling system & how cannabis is safer statistically than opiates that are schedule 2. Some media outlets went as far as to paint a “glass half full” picture. The LA Times for example did a piece titled “DEA ends its monopoly on marijuana growing for medical research.” The social reaction from cannabis enthusiasts, advocates and potrepreneurs from Main Street to Wall Street was as expected with everyone chiming in on social media to wag their fingers at the DEA. Representative Barbara Lee, a congresswoman from Oakland California stating via tweet “Politicians aren’t doctors or scientists. Marijuana research prohibitions are outdated, unscientific, & dangerous for those who need #MMJ.” As expected the rhetoric from the cannabis side was “The DEA is bad, the War on Drugs is a complete failure, Big Pharma is to blame,” so on and so forth.

IMG_8473

The people aren’t wrong on many of these points. The War in Drugs is a failure when considering addiction has been plateauing since its 1970 inception and US drug control spending is up 2000%, which to date stands at $1.5 trillion dollars. We can go on and on as to where that money went, what industries it created (prison industrial complex), the people it disproportionately targeted (minorities), but that’s a whole other article or book for that matter. Big Pharma however does have its trillion dollars hands in this story, but more on that later as I’ve digressed.

Not to go back and pick on the LA Times click-bate headline of “DEA ends its monopoly on marijuana growing for medical research,” but did it really end the monopoly? Let’s evaluate the idea. Yes, a monopoly is defined as “the exclusive possession or control of the supply or trade in a commodity or service.” The University of Mississippi was in fact in exclusive possession of the NIDA edict to legally grow marijuana and study it. On the surface the Monopoly has ended, but the reality is that we are just switching out the term Monopoly for an Oligarchy. Is an oligarchy any different than a monopoly in the sense that it’s just a smaller group carving out the biggest slices for themselves, eliminating competition by means of out maneuvering or outspending their opponent in an effort to influence policy such as this? Consider that the biggest lobby against the cannabis Industry is the pharmaceutical industry, yet they’re simultaneously studying cannabis for the purpose of synthesizing its many chemical compounds to create their high margin drugs.

Currently, their high margin bread and butter are the opioids for pain management such as OxyContin, Percocet and their generic versions of each. The drug companies are experts at isolating molecules from nature to create drugs that cost pennies to manufactures. In a zero sum game, cannabis is a direct threat to pharma companies, by snatching billions in profit and simultaneously causing billions in losses. Anti-cannabis lobbies would also be at risk as the pharmaceutical giants that feed them down on K Street would lose out on easy paydays. These anti-Marijuana lobbyists provide a micro look at the systemic problems within American politics illustrating how/why elected officials in Congress consistently vote against the interests of their collective constituency and bring forth carefully crafted bills or amendments like this one.

On the DEA’s policy statement and legal considerations section, under, legal applicable considerations it states.

“Second, as with any application submitted pursuant to section 823(a), in determining whether the proposed registrationwould be consistent with the public interest, among the factorsto be considered are whether the applicant has previous experience handling controlled substances in a lawful manner and whether the applicant has engaged in illegal activity involving controlled substances. In this context, illegal activity includes any activity in violation of the CSA (regardless of whether such activity is permissible under State law) as well as activity in violation of State or local law. While past illegal conduct involving controlled substances does not automatically disqualify an applicant, it may weigh heavily against granting the registration.”

Translation, grow marijuana even in a state where it’s legal and you are going to have a hard time becoming a manufacturer or researcher for the DEA’s new policy, thus excluding tier one cultivators in practice and likely creating a perpetual home for cannabis on the scheduling list. Prohibition’s end could very well be right around the corner, but the fear is in the form of legal medical marijuana at a Walgreens near you. I asked the DEA’s Russ Baer directly if the inserted language above in bold would be a non-starter for current cultivators wanting to become manufacturers as they are in clear Violation of CSA? In a written statement to Marijuana Stocks the DEA’s official response was:

“DEA is serious about facilitating marijuana research and that there is a lawful pathway for doing so. This DEA decision will facilitate increased research involving marijuana, within the framework of the law and U.S. treaty obligations, to enhance the drug’s supply available to researchers. The goal of this historic and monumental policy shift is to increase the amount and variety of marijuana available to researchers and make it easier for researchers to obtain marijuana as compared to current system under which marijuana must be obtained from NIDA. Growers must become registered with DEA, following the submission of an application, which DEA will evaluate in accordance with the CSA. Registered growers will need to comply with all CSA regulatory requirements, such as quotas, record keeping, order forms, and maintenance of control against diversion. Marijuana produced under this proposal may only be supplied to DEA-registered manufacturers and researchers, and only for purposes authorized by the CSA.

All potential new drugs, including drug products made from marijuana, are subject to the rigors of the drug approval process mandated by the Federal Food, Drug and Cosmetic Act (FDCA). This drug approval process requires that before a new drug is allowed to enter the U.S. market, it must be demonstrated through sound clinical trials to be both safe and effective for its intended uses,” stated Russ Baer of the Drug Enforcement Agency.

When asked if the inserted language also creates an unfair advantage for Pharma companies the response from the Drug Enforcement Administration circled back to the CSA (Controlled Substance Act) stating that the “DEA has adopted a new policy, consistent with the CSA and U.S. treaty obligations, under which additional entities may become registered with DEA to grow and distribute marijuana for research purposes. DEA will evaluate each application it receives to determine whether adding such applicant to the list of registered growers is necessary to provide an adequate and uninterrupted supply of marijuana to researchers in the U.S. In addition, applicants must demonstrate their ability to safely secure the drugs to prevent diversion, while abiding by the approved research protocol.”

The Controlled Substance Act

Everything points back to the Controlled Substance Act, a bill that was introduced into the Congress by Harley Staggers and took less than 6 weeks to get passed by the Senate and signed into law by President Richard M. Nixon. The signing of this document not only created the “War on Drugs,” but put an enforcement agency (DEA) in charge of Cannabis scheduling, circumventing the FDA in a move that creates an inter-agency firewall of sorts. The DEA’s position on why the FDA, who already regulates pharmaceutical drugs, isn’t in charge of marijuana rescheduling was point blank, “The Controlled Substances Act provides a mechanism for substances to be controlled (added to or transferred between schedules) or decontrolled (removed from control). The CSA provides roles for DEA and the FDA. Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by DEA, HHS, or by petition from any interested party. Once initiated, the process involves a deliberate and collaborative interagency exchange.”

IMG_8472

In Laymen’s terms CSA effectively says “DEA you’re in charge of this, FDA you’re in charge of that.” Unfortunately, Marijuana will never be completely removed from the scheduling list unless there is a major political overhaul in every branch of government, if and only if elected officials stop letting lobbies pour honey in their ears and money into campaigns. The reality from my perspective is that the DEA is a scapegoat, the perfect Boogey Man, simply because their job is to follow orders. They are soldiers in a sense, adhering to the guidelines of the Controlled Substance Act (CSA), a legal document crafted by a congress, molded in the image of benefactors, used to fuel a fake war and create cottage industries.

The DEA knows marijuana is safer than Oxy and that’s not speculation that’s a direct quote. They don’t want to go after the mother transporting medication to her sick child because they’re suffering from seizures. They want the dangerous individuals like El Chapo or the pill mills slinging Oxy off the streets. They have no interest in going after all cultivators following state law to the letter. Are there exceptions, of course! Does it make these comments directly from them any less true? No.
DEA’s direct position on which drug is more dangerous from a consumption standpoint as it relates to Cannabis vs OxyContin? “There were more than 47,000 drug overdose deaths in 2014, or approximately 129 per day, more than half (61 percent) of which involved either a prescription opioid or heroin. Marijuana meets the statuary criteria of a Scheduled I controlled substance, and has been determined to have a high abuse potential with no currently accepted medical use. Schedule I includes some substances that are exceptionally dangerous (including heroin and LSD) and some that are less dangerous (including marijuana, which is less dangerous than some substances in other schedules).” When asked point blank, what’s more dangerous Oxy or Marijuana DEA says “Oxy.”

Robert Capecchi, Director of Federal Lobbying at the Marijuana Policy views medical marijuana legalization as a means to an opioid end as well as fiscal no brainer with far reaching benefits.

“Ending marijuana prohibition will allow licensed businesses to cultivate, distribute, and sell marijuana to adults. Unlike the criminal market, a legal and regulated market means products are pure, tested and labeled, sales are taxed, and business disputes are resolved in the courts, not with violence. Additionally, there is promising evidence to suggest that legal access to medical marijuana reduces the rates of opioid overdoses and the reliance on prescription pain killers.”

Foregone Conclusion?

Prohibition’s end could very well be right around the corner, but would we want it in the form of legal medical marijuana at a Walgreens near you? August 11th’s ruling was either one of many dominos in the quest for the monopolization of cannabis or just a pessimistic idea based off of history repeating itself. Regardless of which reality we are presently in, it doesn’t hurt to try and connect the dots, but if I can leave you with one last thing it’s the number 6630507. In case you’re wondering that’s the United States patent # they filed for cannabis in 2003 citing “multiple therapeutic uses.” I can only postulate why they did that….

Regards,

Jason Spatafora

Drug War

The following is an article highlighting what is in our opinion the best Marijuana Stocks / Cannabis Stocks to Watch in 2017 & Beyond.

Earlier this year we covered the market for marijuana stocks post Trump and many of these marijuana stocks have continued to see progress over the time since. Now that we’re finally through the transitional period, it’s time to look ahead at marijuana stocks to watch in 2017 and even beyond. Who would have thought this industry would have come this far, let alone open up the doors to an entirely new and evolving sector.

In fact, according to new research, North American sales are projected to top $20.2 billion by 2021. Marijuana sales in North America grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expands in the U.S. and Canada, according to a report from Arcview Market Research. So, it’s hard not to find the best marijuana stocks to watch this year and in the years to come.  Several we have watched, mentioned, reported on, and reviewed very recently with favorable market activity in play.

First and foremost, mCig, Inc. (MCIG) is a company we’ve watch grow immensely over the last few months.  Since it was trading around 2 and a half cents in September, MCIG has seen highs of as much as $0.505.  The stock has been upholding a channel roughly between $0.30 and $0.40 for the last few weeks and multiple announcements show, in our opinion, that company’s focus on really building shareholder value including triple digit sales growth, canceling 20 million shares  and converting another 60 million shares into preferred that also carry with it a 2 year lock up.  The company has also announced that it will be reporting on its “record financial growth numbers and cost basis investments; to include, Vapolution, VitaCBD, Omni Health (OTC PINK: OMHE,) Agri-Contractors, and other strategic partnerships.”
The Green Organic Dutchman Holdings Ltd. (TGOD) comes onto this list following the roll-out of our previous coverage on now public company, Emblem Corp (EMMBF). Emblem was one of the most anticipated offerings that has come out of Canada in the last few months.  For TGOD, besides being licensed under the access to cannabis for medical purposes regulations (ACMPR) to cultivate medical marijuana, TGOD has some big names behind it from a financing front including familiar faces from the Emblem & Organigram camps.

In addition to this, the company has 1,000 kg current annual indoor operating capacity as well as a newly acquired property coming in at 75 acres, which adjoins the current facility. The planned IPO of TGOD is in October, more details here.

We looked at OWC Pharmaceutical Research Corp.  (OWCP).  This was trading around $0.95 and recent trading activity has seen this hit as high as $3.23.  The company has most recently been adding to its advisory board.  Both Dr. Sharon Rozenblat and Ms. Miriam Sani, MSc Eng. Dr. Rozenblat will be overseeing the completion of the pre-clinical safety studies on the Company’s treatment for psoriasis, which commenced in November 2016 and Sani is the CEO and owner of “Shefa Amirim” Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. The company itself focuses on two things: 1. medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines and 2. OWCP is developing unique delivery systems for the effective delivery and dosage of medical cannabis.

Rocky Mountain High Brands (RMHB) is another company we’ve watched since the days it was called Totally Hemp Crazy and ever since, we’ve seen this company grab attention of the market.  The company specialized in hemp infused beverages and more recently an alkaline water called Eagle Spirit, which was issued a trademark on Feb 22. Aside from this, the company has been implementing a partnership strategy, enhancing its internal fulfillment operations, as well as making it a known presence at industry conventions.  As of Wednesday 2-22-2017, shares of Rocky Mountain High had hit highs of $0.118.

Advantis Corp. (ADVT) was a company we started watching last summer and since the beginning of the year, we picked back up on it.  There’s enough going on here in our opinion to take notice of including the recent announcements that the company has taken steps to become a fully-reporting public company as well as launched distribution of topical cannabis roll-on and Tinctures to treat pain conditions. This also comes as the company has begun to further expand on its overall product offering so just like we cited at first “way back when” with Totally Hemp Crazy, we think that ADVT could be another company to follow during its infancy.  Since we picked back up on this, we’ve also watched as ADVT climbed from around $0.005 to highs of $0.035 during the last full week of February.

UbiquiTECH Software Corp. (UBQU) was another company we mentioned a few months ago and saw it promptly run from under $0.015 to highs of $0.04.  Of course the market saw pull back but now the new price channel might be hovering closer to 0.02 than 0.01 where it was at late last year.  Fundamentally speaking, the company has announced several new CBD products, paying down thousands of dollars in debt, as well as realizing significant revenue growth of 35% as well as an increase in earnings of 840% compared to that of 2015.  Compared to the company’s annual revenue of $3,493,113, UBQU saw a recognizable jump from the 4th quarter were 35% of the company’s total revenues for the year.  Further UBQU’s last 3 quarters leading up to the most recent filing show quarter over quarter revenue growth and report a net income for the year of over $330,000

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF) made our list a few months ago and it has kept its spot especially considering the move for Canada’s legalization. The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. In addition to partnership and collaboration deals with the like of companies like Radient Technologies (RTI.V), this company has also obtained significant financial contributions through its bought deal private placement with a syndicate of underwriters led by Canaccord Genuity Corp. for aggregate gross proceeds to Aurora of $60,007,500.

Other Canadian marijuana stocks to watch include Canopy Growth (WEED.TO), which just announced that it has entered into a memorandum of understanding with Namaste Technologies Inc. “to define the intention of Namaste and Canopy to expand their respective market positions by seeking to form multi-point working arrangements and exploring the development of new delivery devices for the consumption of cannabis.”

Namaste’s database consists of approximately 300,000 customers that generate upwards of 600,000 site visits monthly. Namaste also has 26 e-commerce retail stores in 20 countries. We watch now in the midst of all of the developments as Canopy has grown from a stock trading under $3 to today’s price of more than $12/share.

Future Farm (CSE: FFT) (OTCQB: FFRMF) formerly AGSTF, this company is something we’ve covered from very early on.  This company has been aggressively expanding into the marijuana space.  The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment.  We began following this at $0.137 and this week it has managed to hit highs of $0.50; a solid run of 265% so far and could certainly be something to be watching into 2017.

Similar to Aurora, Aphria, Inc. (APH.V) (APHQF) has entered into an agreement with Clarus Securities to which the Underwriters have agreed to purchase, on a “bought deal” basis, 10,000,000 Common Shares of the Company at a price of C$5.00 per Common Share for aggregate gross proceeds to the Company of C$50,000,000. This is expected to close on or about February 24 of this year. The company also recently received approval to jump from the TSX Venture Exchange to list on the TSX and depending on meeting certain conditions, is expected to be finalized on or before the TSX imposed May 3rd, 2017 deadline. The stock on the US exchange and the Canadian exchange has been on an uptrend since last March.

0 1314

*BIG NEWS FROM $VNNYF*
Company To Acquire 65% of Health Canada and FDA Licensed Laboratory

 

Vinergy Resources Ltd. (CSE:VIN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ BioPharma (announced December 14, 2016) is pleased to announce that, as a part of the Company’s strategy to develop products that test and identify specific cannabinoid isolates for targeted therapeutic purposes it has signed a binding Letter of Intent (“LOI”) to acquire 65% of Biolennia Laboratories Inc.!

This is a fantastic acquisition for us and supports our entire product line and R&D initiatives moving forward. Our technical expertise in drug testing, extractions, and formulas containing CBD, Terpene, THC and other botanicals is continually being furthered. We have a remarkable team. We feel strongly that science based products formulated from extracts and derivatives that are properly dosed and manufactured in GMP environments to ensure consistency and safety for all customers whether they be recreational or medical users, is the future of the cannabis industry,” MJ BioPharma CEO Kent A. Deuters.

 


*Click Here Now To Read Full PR*


$UBQU Announces New Third Party Verification of its CannazALL Products


Ubiquitech Software Corp. ( OTC PINK : UBQU ), through its subsidiary HempLife Today™, is announcing a very important step in streamlining a new process for verification of its CannazALL™ CBD products to help boost sales and greater overall consumer trust in its popular CannazALL™ brand.

Under this new development all CannazALL™ CBD products will continue to be internally and third-party tested and a new retrieval process will be created so that new and existing consumers have additional clarification on the quality of the products they are ordering and consuming. The company believes that giving consumers easier access to this information will help boost consumer confidence which should naturally result in additional sales, repeat orders, and a boost in revenues.


Click Here To View Full Press Release



$MCIG Announces New Date for Conference Call

 

mCig Inc. (MCIG) announced today that, due to the closing of a significant transaction this week, management has elected to postpone the scheduled shareholder call one week, which will now be held on Tuesday, March 7, 2017 at 4:30 P.M. Eastern Time (ET). MCIG will discuss our outstanding third quarter numbers, the recent developments with our cost basis investments, and our future growth plans and vision. The event will include a panel discussion with the MCIG management team.


Click Here To Read Full PR


 

CBD Offers A Natural Anti-anxiety, Antipsychotic, And Anti-epileptic Effect

It seems people are searching for peace, tranquility, and a sense of overall well being these days. There is so much anxiety in combination with the instability of the the economy, government, the weather, and life in general is overwhelming for many of us. The pursuit is always to find that natural high, whether from yoga, meditation, running, or anything that gets the blood moving and oxygen flowing...[continue reading]


Click Here Now To Read Full Article


Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market.MAPH owns 2 million restricted common shares of MCIG Inc. We may buy or sell additional shares of (UBQU,MCIG,VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 1126

Easton Pharmaceuticals / BMV Medica Announces Successful Product Sales Launch Conference Of Product Gynofit and Additional Distribution of Product AL-Sense (AmnioSense) With Multi-National Pharmaceutical Company Gedeon Richter

Easton and BMV representatives attended a product sales conference launch, held last week by partner Gedeon Richter and their Mexican / Latin American subsidiary, Gedeon Richter Mexico S.A.P.I. de C.V., at the Hilton Puerto Vallarta. This product sales launch was for the recently signed distribution agreement of Easton / BMV’s Gynofit product for Mexico, which Gedeon is commencing. The product sales launch conference was attended by approximately 65 fulltime sales reps as Gedeon Richter allocated considerable resources towards a very detailed and professional sales presentation, which included product packaging, videos, literature and educational material describing BV (Bacterial Vaginosis) and how “Gynofit” can not only treat the condition, but prevent and provide a healthy Vaginal Flora. BV (Bacterial Vaginosis) is projected to affect almost all woman at least once in their lifetime, with many being treated for BV (Bacterial Vaginosis) several times as more awareness and education is gathered on the condition. An estimated 65 full time sales reps are being deployed to sell “Gynofit” throughout Mexico with other Latin American countries expected to soon be introduced. Easton / BMV has now delivered the first PO shipment of “Gynofit” to Gedeon for their product launch.

In the week prior to the “Gynofit” sales launch conference, Easton / BMV met with representatives of multi-national pharmaceutical company, Gedeon Richter, Mexico President in New York City, as part of negotiations to sign an additional exclusive distribution agreement, whereby Gedeon Richter, Mexico, would distribute Easton / BMV’s AL-Sense (AmnioSense) product which Easton / BMV hold licensing rights for in Mexico and many other parts of central and South America. These negotiations continued in Puerto Vallarta this past week with an agreement expected to be finalized in the coming days. Gedeon Richter Plc and their Mexican / Latin American subsidiary Gedeon Richter Mexico S.A.P.I. de C.V. have provided a proposal to Easton / BMV for distribution of AmnioSense for Mexico. Pricing, packaging, logistics and an estimated launch date of AL-Sense were discussed and agreed to, which would result in an expected launch of AL-Sense for June / July of this year with an anticipated PO to be provided to Easton / BMV in March or April following the signing of the distribution agreement.

AL-Sense (AmnioSense) is an Amniotic Fluid Diagnostic Leak Test which is a patented women’s diagnostic product that is currently being sold in the United Kingdom, and has European Approval. It serves a huge market, and the birth rate in Latin America is three times the birth rate in North America and most of Europe. The target market for Easton / BMV has a population exceeding 200 million people. Sales in Latin America for pharmaceutical and diagnostic products are expected to grow at a rate five times that of North America and Europe as a result of a much higher birthrate in the region as well as other factors.

For More Detailed Information on Gedeon Richter Plc Visit:

http://www.richter.hu/en-US/Pages/default.aspx

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton together with BMV Medica SA de C.V., own the exclusive distribution rights in Mexico and Latin America for patented women’s diagnostic and preventative care products from CommonSense Of Israel, along with two generic cancer drugs, Paclitaxel and Docetaxel from BioLyse Pharma of St. Catherine’s Ontario, Canada. Easton is also involved in the lucrative Medical Marijuana industry, as well as attempting to acquire several other highly profitable revenue generating complimentary businesses.

0 4648

 

LEARN The Basics of How to Trade / Invest in the Stock Market (BEGINNERS ONLY)

 

We get hundreds of emails per day asking us how to invest in public MJ companies. Everyday our subscribers ask us how to start trading stocks. We’ve heard you loud and clear.

 


Click Here To Find Out More

 




$ADVT: New Bull Trend Confirmed?

 

 

Yesterday we updated everyone on our continuing coverage of ADVT. This was a sub penny when we began watching it a few months ago and since then, the recent trump bump seems to have taken hold. Yesterday the company announced that it is taking steps to become a fully-reporting public company.  During yesterday’s trading session alone, ADVT gained over 20% and just like the last time we started to follow an MJ company like this, it could be just the beginning.

 


Click Here To View Full Release




#ICYMI: $GRWC Secures $450,000 in Bridge Financing focusing on the build out of its Smoke on the Water brand

 

Yesterday we published the latest news from GRWC which outlined the next step and financial commitment for their build out of Smoke on the Water. After 5 consecutive days of a downward trend, GRWC began to see a reversal, which could be the start of a turn-around on the chart. We’ll continue to keep you updated with more developments on this.

 


Click Here To View Full Release


 

The Green Organic Dutchman Holdings Ltd. Provides Shareholder Update And Announces $10 Million Non-Brokered Financing

 

It is with great pleasure that I address you today as shareholders of our company, The Green Organic Dutchman Holdings Ltd. (“TGOD”). Our Company has recently made major developments that I would like to report on. Additionally, I would like to announce a new financing.

 


Click Here To View Full Article

 


 

 

$MCIG Strengthens Share Structure Announces Shareholder Call

 

mCig Inc., ( OTCQB : MCIG ), a diversified company servicing the legal cannabis, hemp, and CBD markets, came into a significant agreement with several MCIG’s major shareholders to reduce its common stock by 60 million shares by converting those shares into 6 million Series A Preferred Stock with a minimum 2 year lock up agreement. Paul Rosenberg, MCIG’s Chief Executive Officer, has also agreed to cancel an additional 20 million underlying common shares to further reduce the outstanding shares.

 


Click Here To View Full Release


 

$HEMP Updates and Announcements

 

Hemp, Inc. ( OTC PINK : HEMP ) executives are pleased to update its shareholders on the booming industrial hemp industry across the globe and how it is set to stimulate the economy on a national and global scale. Bruce Perlowin, CEO of Hemp, Inc. says ramping up hemp production on American soil, in particular, will serve as a stimulus for many ancillary industries from packaging and distribution to logistics and marketing. “The industrial hemp industry creates a win-win for all,” says Perlowin. However, until the federal ban is lifted in the U.S., organizations and advocates continue to educate the public on hemp and its benefits.

 


Click Here For Full PR

 




 

 

Pursuant to an agreement between MAPH and Grow Condos, we were hired for a period of 30 days to publicly disseminate information about (GRWC) including on the Website and other media including Facebook and Twitter. We are being paid $50,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (GRWC) which we purchased in the open market. MAPH owns 6 million restricted common shares of HEMP Inc. and 2 million restricted common shares of MCIG Inc. We may buy or sell additional shares of (GRWC, HEMP, MCIG) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 1525

American Cannabis Company, Inc. Announces It Has Secured A Contract And Equity Stake With A New Client In The State Of Pennsylvania

American Cannabis Company, Inc. ( OTCQB : AMMJ ) (the “Company”), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced it has secured its sixth client in the state of Pennsylvania. The Company will work with this client to strategically plan, deploy and remotely oversee the client’s retail dispensing, cultivation and infused product manufacturing operations within the city of Philadelphia. In addition to the Company’s consulting engagement, the Company will also be taking an equity interest in the client’s project and operations.

The Company will provide end-to-end solutions for this new client, which include operational planning activities, conceptual design work, application completion, deployment of operations and ongoing remote management. The Company expects to leverage this contract to secure additional revenues through long-term consulting agreements and potential future sales of ancillary products.

Terry Buffalo, CEO of American Cannabis Company, commented: “We are excited to be working with this particular client, as well as collaborating with them by taking an equity position in their business. The Company is actively exploring the development of hybrid relationships like this, that generate both consulting revenues and the opportunity for recurring profits from our equity interest. We feel that this new strategy will provide a beneficial long-term value to both our clients and our shareholders.”

About American Cannabis Company, Inc.

American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis industry. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and operational best practices. American Cannabis Company also developed and owns a portfolio of branded products including: The Satchel™, Sohum Living Soils™, The Cultivation Cube™ and The High Density Cultivation System™. We also design and provide other industry specific custom product solutions. The building and development of our brands and product suite is based on our Geoponics Philosophy, “the art and science of agriculture in soil.”

For more information, please visit:

www.americancannabisconsulting.com
www.americancannabiscompanyinc.com
www.sohumsoils.com
www.dabwerks.com

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

1 2970

 

$VNNYF ($VIN) to Acquire Majority Stake in Multinational Plant Breeder

On the heels of their latest announcement that Vinergy Resources has officially obtained a US ticker symbol and will commence trading on the OTCQB, Vinergy Resources Ltd. (CSE:VIN)(CSE:VIN.CN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce today that it has signed a Letter of Intent (LOI) to acquire up to 51% of a European multinational plant breeding company (“Target”). The Target has audited annual sales in excess of CAD $14,000,000 and adjusted EBITDA of over CAD $2,000,000.

 


Click Here To View Full PR


 

More Conditions Could be Added to List to Obtain Medical Marijuana

Virginia’s Senate recently voted to broaden the use of cannabis oil for medical purposes after a deliberation that shifted into presidential drug usage, 1960s hippie culture, and the long list of possible side effects communicated on some TV pharmaceutical ads. The bill, co-sponsored by Sen. Jill Holtzman Vogel and Senator Barbara A. Favola, builds on legislation passed two years ago that was meant to make it easier for Virginians with serious forms of epilepsy to use the oils that come from cannabis.

 


Click Here To View Full Article


 

#ICYMI: Cannabidiol Oil Will Not Be Affected By DEA Rescheduling

Reports of hemp-based CBD medicine’s death have been highly exaggerated. That’s the word from several legal experts who say, despite a moment of industry-wide panic about the DEA’s filing of a memo with the federal register establishing a “final rule” on the internal classification of “marijuana extracts” the law regarding CBD and hemp has not changed. A memo from Folium Legal Counsel reflects this widespread interpretation of the law and the lack of negative impacts on the industry since the filing took effect.

 


Click Here To View Full Article


 

PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 3220

$VBIO Publishes Scientific Data on Discovery of Cannabinoid Glycosides

Vitality Biopharma, Inc. ( OTCQB : VBIO ) (“Vitality Biopharma”, “Vitality”, or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced the publication of a scientific manuscript that details internal research efforts including the discovery and production of cannabinoid glycosides.

 


Click Here To View Full PR


 

$VPRB LP is partnering with Alpha-Cat

VPR Brands, LP (OTC PINK: VPRB), entered into an exclusive distribution and sales agreement with Alpha-Cat, the creator of the AlphaPuff all in one deluxe smoker’s kit. VPR Brands will represent the patent pending innovative all in one Cannabis water pipe travel kit by strategically introducing it within its distribution pipeline, showcasing it at large cannabis / smoking trade events, and further working with Alpha-Cat to continuously innovate on this revolutionary concept.

 


Click Here To View Full PR


 


$MCIG Announces $200,000 Investment from CEO and CFO

mCig Inc., ( OTCQB : MCIG ), a diversified company servicing the legal cannabis, hemp, and CBD markets, announced today it has entered into legally binding subscription agreements with Paul Rosenberg, Chairman and Chief Executive Officer and Michael Hawkins, Chief Financial Officer for the issuance of 25,000 newly issued Series A Preferred shares each. Under the agreements Mr. Rosenberg and Mr. Hawkins will subscribe for and purchase directly or through their own beneficially owned and controlled special purpose vehicle 25,000 shares of Series A Preferred stock each for a total purchase price of $200,000 ($100,000 each), or $4.00 per share, which equates to $0.40 per common share in conversion. In addition to the Series A Preferred stock, Mr. Rosenberg and Mr. Hawkins will each receive a five year warrant for an equal amount of common shares at $0.75 per share.

 


Click Here To View Full PR


 

Cannabidiol Oil Will Not Be Affected By DEA Rescheduling

Reports of hemp-based CBD medicine’s death have been highly exaggerated. That’s the word from several legal experts who say, despite a moment of industry-wide panic about the DEA’s filing of a memo with the federal register establishing a “final rule” on the internal classification of “marijuana extracts” the law regarding CBD and hemp has not changed. A memo from Folium Legal Counsel reflects this widespread interpretation of the law and the lack of negative impacts on the industry since the filing took effect.

 


Click Here To View Full Article


 

 PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 3054




Get the Full Picture, View in a Browser

Get MJ News, Articles, Picks & Alerts Instantly. From Your Cell Phone Text the Word “MJSTOCKS” to 82257

Advocates in Indiana See Hope In Medical Cannabis Hearing


When the state Legislature allowed a Senate committee to hear testimony on an Indiana medical cannabis-related bill, enthusiasts saw…



Click Here To View Full Article



$MCIG Cannabis & CBD’s Revenue Net Positive



MCIG has reached an important inflection point of controlled expenses, improved off take, and overall profitability. It has signed minimum order quantity…



Click Here To View Full News



$FBEC Announces Exclusive Agreement with New Co-Packer NVE Pharmaceuticals Developer of Stacker 2


FBEC Worldwide, Inc. (FBEC), a lifestyle brand company with a focus on Healthy Hemp Energy™ & CBD infused consumer products, is pleased to announce that on January 5, 2017 FBEC Worldwide, Inc. entered a new co-packing agreement with NVE Pharmaceuticals, the manufacturer of Stacker 2.



Click Here To View Full News



$UBQU Pays Down $65,000 Debt since January 1st, 2016



Ubiquitech Pays Down $65,000 Debt since January 1st, 2016; Anticipates Continuing This Trend of Debt Repayment Throughout the Year…


Click Here To View Full News




0 2445

 


Get MJ News, Articles, Picks & Alerts Instantly. From Your Cell Phone Text the Word “MJSTOCKS” to 82257
 

Why Are Executive Positions In The Marijuana Industry So Popular For Women?

The number of women in executive positions in the marijuana industry is astonishing. According to a study of 632 marijuana executives conducted by the Marijuana Business Daily in 2015, women are in leadership positions in…

 


Click Here To View Full Article


 

Californians Fighting Delays Of Recreational Cannabis Use

California farms, sells, and consumes billions of dollars worth of cannabis. For more than ten years, medicinal cannabis cardholders have been able to purchase…

 


Click Here To View Full Article


 

GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 7 February, 2017

GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 7 February, 2017 GW Pharmaceuticals plc (GWPH) (“GW” or “the Company”), a biopharmaceutical…

 


Click Here To View Full News


 

 

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements